



## Ovarian Cancer: From Mechanisms to Novel Target Therapies

Guest Editor:

**Dr. Yi-Hui Wu**

Department of Medical Research,  
Chi Mei Medical Center, Tainan,  
Taiwan

Deadline for manuscript  
submissions:

**closed (1 January 2025)**

### Message from the Guest Editor

Epithelial ovarian cancer (EOC) is the leading cause of gynecologic malignancy-related deaths worldwide. Despite advances in multidisciplinary treatment, the overall mortality has remained steady over the past thirty years. Most EOC patients are diagnosed at an advanced stage, and they eventually develop chemo-resistant relapsed disease despite surgery and combination chemotherapy. To date, the mechanism underlying chemo-resistance in ovarian cancer remains unclear. In addition, ovarian cancer falls under a heterogeneous group of malignancies that arise from various cell types, and the genetic mechanisms involved in chemo-resistance should be complex and differentially defined among different subtypes of ovarian cancer. Thus, to develop novel therapeutic strategies, it is crucial to define reliable predictive biomarkers for different subtypes and therapeutic resistance.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)